<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880293</url>
  </required_header>
  <id_info>
    <org_study_id>16-1237</org_study_id>
    <nct_id>NCT02880293</nct_id>
  </id_info>
  <brief_title>Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor</brief_title>
  <official_title>Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study will test whether half matched donors with favorable KIR genes will reduce the
      risk of cancer recurring after transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 23, 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients undergoing an allo HCT transplant who have a KIR favorable donor.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>melphalan (140 mg/m2 IV on day -7)</description>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>Alkeran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
    <description>fludarabine (40 mg/m2/d on days -5 through -2)</description>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>FLUDARA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>thiotepa (5 mg/kg IV on day -67)</description>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide (50 mg/kg IV on day +3 and +4)</description>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>Mesnex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>(15 mg/kg PO/IV TID)</description>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>CellCept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Patients will undergo donor/recipient bone marrow</arm_group_label>
    <other_name>Prograf®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with any of the following hematologic malignancies who are considered to be
        eligible for allogeneic transplantation:

          -  Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high riskfor
             relapse including:

          -  t(9;22) or detected BCR-ABL1 translocation by genomic methodologies

          -  BCR-ABL1-Like B-ALL [54] including mutations of IKZF1 or CRLF2

          -  Translocations or mutations involving 11q23 (MLL) gene.

          -  Hypodiploid karyotype

          -  Deletion of 9p

          -  Loss of 17p or TP53 mutation

          -  T-lymphocyte lineage antigen expression (T-ALL)

          -  CNS or other extramedullary involvement

          -  WBC count &gt;/= 100,000 cells/μL at diagnosis

          -  Relapsed ALL, biphenotypic/bilineal leukemia, or AML with &lt;/= 10% blasts in the bone
             marrow prior to transplantation

          -  Acute biphenotypic or bilineal leukemia in first or greater complete remission.

          -  Acute myeloid leukemia (AML) in CR1 with intermediate or high risk features including:

          -  Cytogeneic abnormalities associated with myelodysplatic syndrome including
             abnormalities of chromosome 5 or 7

          -  History of anti-neoplastic therapy (radiation or chemotherapy)

          -  Extramedullary involvement

          -  WBC count &gt;/= 100,00 cells/ul at diagnosis

          -  Rearrangements or mutations of 11q23 (MLL)

          -  Abnormalities of chromosome 3

          -  TP53 mutation or loss of 17p

          -  Complex or monosomal karyotype

          -  Normal karyotype with mutations of FLT3, RUNX1, or ASXL1

          -  Myleodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome
             with:

          -  International prognostic scoring system risk score of INT-2 or high risk at the time
             of transplant evaluation

          -  Any risk category if life-threatening cytopenia exists

          -  Karyotype or genomic changes that indicate high risk for progression to acute
             myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53,
             or complex or monosomal karyotype

          -  Myelofibrosis with DIPSS scores of INT-2 or high risk or any risk category if life
             threatening cytopenias are present

          -  Chronic myelomonocytic leukemia (CMML)

          -  Chronic myeloid leukemia (CML) who have failed or are intolerant to BCR-ABL tyrosine
             kinase inhibitors

          -  CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition
             (e.g. T351 l mutation)

          -  CML with accelerated or blast phase with &lt;20% blasts after therapy

          -  Hodgkin lymphoma:

          -  Relapsed disease with progression after autologous bone marrow transplant or are
             ineligible for this procedure

          -  Responding to therapy prior to enrollment

          -  Non-Hodgkin lymphoma:

          -  Responding to therapy prior to enrollment

          -  Progression after autologous bone marrow transplant or are ineligible for this
             procedure

          -  Chronic lymphocytic leukemia with high risk disease as defined by the EBMT consensus
             criteria

               -  Patients aged 18 through 69 years old are eligible

               -  Patients aged 70-75 with HCT-CI of 0-1 are eligible

               -  High risk hematologic malignancies

               -  Patients must have Karnofsky performance status &gt;/= 70%

               -  Cardiac left ventricular ejection fraction &gt;/= 50% at rest

               -  Total bilirubin &lt;/= 2 mg/dL, except for patients with Gilbert's syndrome

               -  AST and ALT &lt;/= 5x ULN unless thought to be disease related

               -  Estimated or measured creatinine clearance &gt; 50 mL/min

               -  Hemoglobin adjusted pulmonary DLCO &gt;/= 50% of predicted

        Exclusion Criteria:

          -  Persons with a HLA matched sibling donor.

          -  Female patients who are pregnant or breast-feeding

          -  Persons with an infection that is not responding to antimicrobial therapy

          -  Persons who are seropositive for HIV.

          -  Persons with uncontrolled central nervous system malignancy •Persons who do not meet
             the age and organ function criteria specified above Presence of psychiatric or
             neurologic disease, or lack of social support that limits the patient's ability to
             comply with the treatment protocol including supportive care, follow-up, and research
             tests.

          -  Prior diagnosis of non-hematologic malignancy within 5 years of planned protocol
             therapy EXCEPT:

               -  Diagnosis of breast ductal carcinoma in situ treated with curative intent

               -  Diagnosis of prostate adenocarcinoma with Gleasons score &lt;/= 6 treated with
                  curative intent

               -  Non-melanomatous skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Shaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Shaffer, MD</last_name>
    <phone>212-639-2212</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Shaffer, MD</last_name>
      <phone>212-639-2212</phone>
    </contact>
    <investigator>
      <last_name>Brian Shaffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplant conditioning</keyword>
  <keyword>KIR/HLA based haploidentical donor selection</keyword>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

